Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer
Karine Pozo(The University of Texas Southwestern Medical Center), James Bibb(University of Arizona)
Cited by 6
Related Papers
Memory Enhancement by Targeting Cdk5 Regulation of NR2B
|Neuron|2014|133
Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis
|Oncotarget|2015|30
Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
|Frontiers in Pharmacology|2022|22
Genetic impairment of succinate metabolism disrupts bioenergetic sensing in adrenal neuroendocrine cancer
|Cell Reports|2022|16
Cdk5 mediates rotational force-induced brain injury
|Scientific Reports|2023|11